<DOC>
	<DOCNO>NCT00922428</DOCNO>
	<brief_summary>The purpose observational study give overview use PASCOE-Agil HOM-Injektopas 2-4 week treatment rheumatic disorder .</brief_summary>
	<brief_title>PASCOE-Agil HOM-Injektopas Treatment Rheumatic Disorders</brief_title>
	<detailed_description>The purpose observational study give overview use PASCOE-Agil HOM-Injektopas 2-4 week treatment rheumatic disorder different aetiology localisation , display variety symptom . Efficacy tolerability drug assess . Special regard take administration management relation Summary Product Characteristics ( SmPC ) .</detailed_description>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Due design Observational Study inclusion exclusion criterion therapy name . The included patient group describe `` Cohort / Group '' . Observational Criteria ( =inclusion criterion documentation ) : Males female At least 18 year old Rheumatic disease accompany symptom , e.g . arthralgia , myalgia , lumbago etc . Exclusion criterion documentation : young 18 year Rheumatic disease accompany symptom , e.g . arthralgia , myalgia , lumbago etc . treatment PASCOEAgil HOMInjektopas</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>rheumatism</keyword>
	<keyword>arthralgia</keyword>
	<keyword>myalgia</keyword>
	<keyword>lumbago</keyword>
	<keyword>homoeopathy</keyword>
	<keyword>injection</keyword>
	<keyword>PASCOE-Agil HOM Injektopas</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>acceptance</keyword>
	<keyword>safety</keyword>
</DOC>